|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.52 CHF | -0.39% |
|
-1.30% | -0.41% |
| Apr. 18 | NOVARTIS AG : UBS reiterates its Buy rating | ZD |
| Apr. 18 | TotalEnergies: shareholders want to separate powers | CF |
May 17 (Reuters) - The U.S. Supreme Court on Monday dashed Novartis AG's hopes of launching a generic version of Amgen Inc's multibillion-dollar rheumatoid arthritis Enbrel, declining to hear the company's challenge to two patents on the drug.
The justices turned away Novartis subsidiary Sandoz Inc's appeal of a lower court decision that upheld the validity of the patents. (Reporting by Andrew Chung in New York; Editing by Will Dunham)
| 1st Jan change | Capi. | |
|---|---|---|
| -0.41% | 204B | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -10.02% | 194B | |
| -11.81% | 144B | |
| -8.80% | 142B |
NOVARTIS AG 
